{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:16:09Z","timestamp":1792725369017,"version":"4.5.0"},"reference-count":257,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer compounds that are widely used in the treatment of hematologic malignancies and solid tumors. Unlike conventional chemotherapeutic drug-based therapies, that are mainly associated with modest specificity and therapeutic benefit, the three key components that form an ADC (a monoclonal antibody bound to a cytotoxic drug via a chemical linker moiety) achieve remarkable improvement in terms of targeted killing of cancer cells and, while sparing healthy tissues, a reduction in systemic side effects caused by off-tumor toxicity. Based on their beneficial mechanism of action, 15 ADCs have been approved to date by the market approval by the Food and Drug Administration (FDA), the European Medicines Agency (EMA) and\/or other international governmental agencies for use in clinical oncology, and hundreds are undergoing evaluation in the preclinical and clinical phases. Here, our aim is to provide a comprehensive overview of the key features revolving around ADC therapeutic strategy including their structural and targeting properties, mechanism of action, the role of the tumor microenvironment and review the approved ADCs in clinical oncology, providing discussion regarding their toxicity profile, clinical manifestations and use in novel combination therapies. Finally, we briefly review ADCs in other pathological contexts and provide key information regarding ADC manufacturing and analytical characterization.<\/jats:p>","DOI":"10.3389\/fphar.2023.1274088","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T03:29:51Z","timestamp":1695094191000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":196,"title":["A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Federico","family":"Riccardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Dal Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Macor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Toffoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8150143","DOI":"10.1155\/2023\/8150143","article-title":"Optimization of the imaged cIEF method for monitoring the charge heterogeneity of antibody-maytansine conjugate","volume":"2023","author":"Abbood","year":"2023","journal-title":"J. Anal. Methods Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"37700","DOI":"10.18632\/oncotarget.26491","article-title":"Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001","volume":"9","author":"Abrahams","year":"2018","journal-title":"Oncotarget"},{"key":"B3","first-page":"4750","article-title":"High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules","volume":"61","author":"Adams","year":"2001","journal-title":"Cancer Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.3390\/cancers14246082","article-title":"Tumor microenvironment in thymic epithelial tumors: A narrative review","volume":"14","author":"Agrafiotis","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1358\/dot.1999.35.12.564040","article-title":"Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer","volume":"35","author":"Albanell","year":"1999","journal-title":"Drugs Today (Barc)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/978-1-4615-0081-0_21","article-title":"Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4","volume":"532","author":"Albanell","year":"2003","journal-title":"Adv. Exp. Med. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/1538-7445.AM2019-221","article-title":"Abstract 221: Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro","volume":"79","author":"Alley","year":"2019","journal-title":"Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","article-title":"Antibody-drug conjugates: targeted drug delivery for cancer","volume":"14","author":"Alley","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1756287220980192","DOI":"10.1177\/1756287220980192","article-title":"Enfortumab Vedotin in urothelial cancer","volume":"12","author":"Alt","year":"2020","journal-title":"Ther. Adv. Urol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","article-title":"Tumor microenvironment antigens","volume":"45","author":"Andersen","year":"2023","journal-title":"Semin. Immunopathol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jbiotec.2020.04.018","article-title":"Modeling of hydrophobic interaction chromatography for the separation of antibody-drug conjugates and its application towards quality by design","volume":"317","author":"Andris","year":"2020","journal-title":"J. Biotechnol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jbiotec.2018.10.003","article-title":"Monitoring of antibody-drug conjugation reactions with UV\/Vis spectroscopy","volume":"288","author":"Andris","year":"2018","journal-title":"J. Biotechnol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2022.06.009","article-title":"Corneal toxicity associated with Belantamab mafodotin is not restricted to the epithelium: Neuropathy studied with confocal microscopy","volume":"242","author":"Aschauer","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.3390\/molecules26102943","article-title":"Antibody\u2013drug conjugates\u2014a tutorial review","volume":"26","author":"Baah","year":"2021","journal-title":"Molecules"},{"key":"B16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"B17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/cbf.1149","article-title":"The role of glutathione in cancer","volume":"22","author":"Balendiran","year":"2004","journal-title":"Cell Biochem. Funct."},{"key":"B18","doi-asserted-by":"publisher","first-page":"106502","DOI":"10.1016\/j.ejps.2023.106502","article-title":"Hybrid liquid chromatography high resolution and accuracy mass spectrometry approach for quantification of antibody-drug conjugates at the intact protein level in biological samples","volume":"188","author":"Barbero","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/c8cs00676h","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/14789450.2019.1578215","article-title":"Cutting-edge multi-level analytical and structural characterization of antibody-drug conjugates: present and future","volume":"16","author":"Beck","year":"2019","journal-title":"Expert Rev. Proteomics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-1-4939-9929-3_19","article-title":"Purification of ADCs by hydrophobic interaction chromatography","volume":"2078","author":"Becker","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"LBA1","DOI":"10.1200\/jco.2012.30.18_suppl.lba1","article-title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane","volume":"30","author":"Blackwell","year":"2012","journal-title":"JCO"},{"key":"B26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1208\/s12248-015-9738-4","article-title":"Antibody drug conjugates: Preclinical considerations","volume":"17","author":"Bornstein","year":"2015","journal-title":"AAPS J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.breast.2020.04.005","article-title":"Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice","volume":"52","author":"Bouwer","year":"2020","journal-title":"Breast"},{"key":"B28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1021\/acs.oprd.3c00136","article-title":"Drug-linkers in antibody\u2013drug conjugates: Perspective on current industry Practices","volume":"27","author":"Bulger","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/19420862.2019.1624127","article-title":"Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis","volume":"11","author":"Cao","year":"2019","journal-title":"MAbs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/PPO.0b013e318172d704","article-title":"Antibody-drug conjugates for cancer therapy","volume":"14","author":"Carter","year":"2008","journal-title":"Cancer J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jconrel.2012.01.026","article-title":"Antibody-drug conjugates: basic concepts, examples and future perspectives","volume":"161","author":"Casi","year":"2012","journal-title":"J. Control Release"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e00535","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"B35","doi-asserted-by":"publisher","first-page":"108106","DOI":"10.1016\/j.pharmthera.2021.108106","article-title":"Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential","volume":"236","author":"Ceci","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: Enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted cancer therapy: conferring specificity to cytotoxic drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1021\/acs.analchem.8b04699","article-title":"Native reversed-phase liquid chromatography: A technique for lcms of intact antibody-drug conjugates","volume":"91","author":"Chen","year":"2019","journal-title":"Anal. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jchromb.2016.07.023","article-title":"Antibody-drug conjugate characterization by chromatographic and electrophoretic techniques","volume":"1032","author":"Chen","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"B42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jconrel.2020.08.021","article-title":"Antibody and antibody fragments for cancer immunotherapy","volume":"328","author":"Chen","year":"2020","journal-title":"J. Control Release"},{"key":"B43","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.chembiol.2013.04.007","article-title":"DNA-Damaging agents in cancer chemotherapy: serendipity and chemical biology","volume":"20","author":"Cheung-Ong","year":"2013","journal-title":"Chem. Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","article-title":"Improved tumor penetration and single-cell targeting of antibody drug conjugates increases anticancer efficacy and host survival","volume":"78","author":"Cilliers","year":"2018","journal-title":"Cancer Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-drug conjugates: Future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired resistance to antibody-drug conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B47","article-title":"The development and causes of cancer","volume-title":"The cell: A molecular approach","author":"Cooper","year":"2000"},{"key":"B48","doi-asserted-by":"publisher","first-page":"S1287","DOI":"10.1016\/j.annonc.2021.08.2087","article-title":"LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study","volume":"32","author":"Cort\u00e9s","year":"2021","journal-title":"Ann. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1586\/17474086.2016.1143771","article-title":"Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia","volume":"9","author":"Dahl","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3390\/molecules25122861","article-title":"Antibody-drug conjugates and targeted treatment strategies for hepatocellular carcinoma: A drug-delivery perspective","volume":"25","author":"Dahlgren","year":"2020","journal-title":"Molecules"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","article-title":"Evolving strategies for target selection for antibody-drug conjugates","volume":"32","author":"Damelin","year":"2015","journal-title":"Pharm. Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/ph11020032","article-title":"Antibody-drug conjugates for cancer therapy: Chemistry to clinical implications","volume":"11","author":"Dan","year":"2018","journal-title":"Pharm. (Basel)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.chroma.2018.12.020","article-title":"Is hydrophobic interaction chromatography the most suitable technique to characterize site-specific antibody-drug conjugates?","volume":"1586","author":"D\u2019Atri","year":"2019","journal-title":"J. Chromatogr. A"},{"key":"B55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jchromb.2019.04.012","article-title":"A method to directly analyze free-drug\u2013related species in antibody-drug conjugates without sample preparation","volume":"1116","author":"de Mel","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1951427","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody-drug conjugates: Promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"MAbs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"10674","DOI":"10.1021\/ac502593n","article-title":"Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment","volume":"86","author":"Debaene","year":"2014","journal-title":"Anal. Chem."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: First approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: First global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"B60","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/0008-5472.CAN-06-2531","article-title":"Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent","volume":"67","author":"Dennis","year":"2007","journal-title":"Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/abt\/tbaa024","article-title":"Tackling solid tumour therapy with small-format drug conjugates","volume":"3","author":"Deonarain","year":"2020","journal-title":"Antib. Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/antib7020016","article-title":"Small-format drug conjugates: A viable alternative to ADCs for solid tumours?","volume":"7","author":"Deonarain","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: Mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"22","author":"Dilawari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B66","doi-asserted-by":"publisher","first-page":"03261","DOI":"10.1007\/s12094-023-03261-y","article-title":"Adverse events of antibody\u2013drug conjugates on the ocular surface in cancer therapy","volume":"2023","author":"Dom\u00ednguez-Llamas","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/978-1-61779-921-1_29","article-title":"Challenges in the development and manufacturing of antibody-drug conjugates","volume":"899","author":"Ducry","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/bit.28066","article-title":"Strategies to control therapeutic antibody glycosylation during bioprocessing: Synthesis and separation","volume":"119","author":"Edwards","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(20)30465-4","article-title":"Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial","volume":"21","author":"Emens","year":"2020","journal-title":"Lancet Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/10408360500523878","article-title":"Glutathione in cancer biology and therapy","volume":"43","author":"Estrela","year":"2006","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/978-1-4939-9929-3_10","article-title":"ADC analysis by hydrophobic interaction chromatography","volume":"2078","author":"Fleming","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1158\/1535-7163.MCT-06-0072","article-title":"A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments","volume":"5","author":"Ferl","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"B76","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/bjc.1983.4","article-title":"Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer","volume":"47","author":"Ford","year":"1983","journal-title":"Br. J. Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/abt\/tby007","article-title":"DNA damaging agent-based antibody-drug conjugates for cancer therapy","volume":"1","author":"Fu","year":"2018","journal-title":"Antib. Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Sig Transduct. Target Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody\u2013drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41419-022-04552-y","article-title":"Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma","volume":"13","author":"Fukuda","year":"2022","journal-title":"Cell Death Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.2217\/fon-2022-0407","article-title":"Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon","volume":"18","author":"Furlanetto","year":"2022","journal-title":"Future Oncol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/01.cji.0000199193.29048.56","article-title":"Immune suppression in the tumor microenvironment","volume":"29","author":"Gajewski","year":"2006","journal-title":"J. Immunother."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to antibody\u2013drug conjugates","volume":"78","author":"Garc\u00eda-Alonso","year":"2018","journal-title":"Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10928-018-9614-9","article-title":"Population pharmacokinetics of inotuzumab ozogamicin in relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"46","author":"Garrett","year":"2019","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B88","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/mabs.1.3.8515","article-title":"Antibody drug-conjugates targeting the tumor vasculature: Current and future developments","volume":"1","author":"Gerber","year":"2009","journal-title":"MAbs"},{"key":"B89","doi-asserted-by":"publisher","first-page":"S307","DOI":"10.1016\/j.bbmt.2019.12.407","article-title":"A novel targeted approach to achieve immune system reset: CD45-Targeted antibody drug conjugates enable autologous HSCT and ameliorate disease in preclinical autoimmune disease models","volume":"26","author":"Gillard","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B90","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1080\/10428194.2020.1786553","article-title":"Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia","volume":"61","author":"Godwin","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"B91","doi-asserted-by":"publisher","first-page":"8947","DOI":"10.3390\/ijms22168947","article-title":"The role of Fc receptors on the effectiveness of therapeutic monoclonal antibodies","volume":"22","author":"Gogesch","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0149-2918(00)88288-0","article-title":"Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin. Ther."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1841393","DOI":"10.1080\/2162402X.2020.1841393","article-title":"Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death","volume":"9","author":"Gomes-da-Silva","year":"2020","journal-title":"Oncoimmunology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1517\/14728222.2013.740461","article-title":"Cathepsin B as a cancer target","volume":"17","author":"Gondi","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"B95","doi-asserted-by":"publisher","first-page":"a022608","DOI":"10.1101\/cshperspect.a022608","article-title":"Microtubules and microtubule-associated proteins","volume":"10","author":"Goodson","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B96","article-title":"Trastuzumab, in StatPearls (treasure island (FL): StatPearls publishing)","author":"Greenblatt","year":"2023"},{"key":"B97","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e0195823","DOI":"10.1371\/journal.pone.0195823","article-title":"Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate","volume":"13","author":"Herbener","year":"2018","journal-title":"PLoS One"},{"key":"B102","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/10600280221118370","article-title":"A review of Tisotumab vedotin-tftv in recurrent or metastatic cervical cancer","volume":"57","author":"Heitz","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"B103","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab soravtansine: First approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"B104","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1182\/blood-2021-151105","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-expressing peripheral T-cell lymphomas","volume":"138","author":"Herrera","year":"2021","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e1395127","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2018","journal-title":"Oncoimmunology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrd3270","article-title":"Antibody-drug conjugates for cancer: poised to deliver?","volume":"9","author":"Hughes","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3390\/pharmaceutics15082017","article-title":"Antibody\u2013drug conjugates: Ushering in a new era of cancer therapy","volume":"15","author":"Hurwitz","year":"2023","journal-title":"Pharmaceutics"},{"key":"B108","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/B978-0-08-100623-8.00041-4","article-title":"Chapter 40 - process development and manufacturing of antibody-drug conjugates","volume-title":"Biopharmaceutical processing","author":"Hutchinson","year":"2018"},{"key":"B109","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol. Biol. Int."},{"key":"B110","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0169-409x(00)00131-9","article-title":"Delivery of molecular and cellular medicine to solid tumors","volume":"46","author":"Jain","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B112","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B113","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1021\/acsomega.8b03627","article-title":"Structural characterization of the aggregates of gemtuzumab ozogamicin","volume":"4","author":"Jiang","year":"2019","journal-title":"ACS Omega"},{"key":"B114","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/ph13090245","article-title":"Antibody\u2013drug conjugates: The last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals"},{"key":"B115","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B116","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s40261-021-01069-8","article-title":"Moxetumomab pasudotox in hairy cell leukaemia: A profile of its use","volume":"41","author":"Kang","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"MAbs"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1703531","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"},{"key":"B120","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br. J. Haematol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2174\/0929867324666170817152554","article-title":"Antibody fragments as potential biopharmaceuticals for cancer therapy: Success and limitations","volume":"26","author":"Kholodenko","year":"2019","journal-title":"CMC"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013drug conjugates: A comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4062\/biomolther.2015.116","article-title":"Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics","volume":"23","author":"Kim","year":"2015","journal-title":"Biomol. Ther. Seoul."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1007\/s11033-018-4427-x","article-title":"Monoclonal antibodies in cancer immunotherapy","volume":"45","author":"Kimiz-Gebologlu","year":"2018","journal-title":"Mol. Biol. Rep."},{"key":"B126","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/ijms22010240","article-title":"Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma","volume":"22","author":"Kitamura","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B127","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/ph14050442","article-title":"The chemistry behind ADCs","volume":"14","author":"Kostova","year":"2021","journal-title":"Pharm. (Basel)"},{"key":"B128","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1080\/10428194.2019.1608536","article-title":"Hairy cell leukemia: present and future directions","volume":"60","author":"Kreitman","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"B129","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B130","doi-asserted-by":"publisher","first-page":"F680","DOI":"10.1152\/ajprenal.00289.2015","article-title":"Human anti-\u03b13(IV)NC1 antibody drug conjugates target glomeruli to resolve nephritis","volume":"309","author":"Kvirkvelia","year":"2015","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: A milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front. Immunol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J. Med. Chem."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody\u2013drug conjugates (ADCs) for personalized treatment of solid tumors: A review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv. Ther."},{"key":"B134","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/cancers12020303","article-title":"CD22 expression in B-cell acute lymphoblastic leukemia: Biological significance and implications for inotuzumab therapy in adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/bloodadvances.2022008303","article-title":"Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia","volume":"7","author":"Le","year":"2023","journal-title":"Blood Adv."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-021-01550-w","article-title":"Loncastuximab tesirine: First approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1021\/acs.bioconjchem.7b00008","article-title":"Tocilizumab-alendronate conjugate for treatment of rheumatoid arthritis","volume":"28","author":"Lee","year":"2017","journal-title":"Bioconjug Chem."},{"key":"B138","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001622-199811000-00012","article-title":"Use of rituximab, the new FDA-approved antibody","volume":"10","author":"Leget","year":"1998","journal-title":"Curr. Opin. Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1021\/acs.bioconjchem.5b00203","article-title":"Targeted delivery of LXR agonist using a site-specific antibody-drug conjugate","volume":"26","author":"Lim","year":"2015","journal-title":"Bioconjug Chem."},{"key":"B140","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-1-62703-541-5_19","article-title":"Determination of charge heterogeneity and level of unconjugated antibody by imaged cIEF","volume":"1045","author":"Lin","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1046\/j.1523-5394.1999.07205.x","article-title":"Perception of chemotherapy side effects cancer versus noncancer patients","volume":"7","author":"Lindley","year":"1999","journal-title":"Cancer Pract."},{"key":"B142","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1515\/mr-2022-0033","article-title":"Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives","volume":"2","author":"Liu","year":"2022","journal-title":"Med. Rev."},{"key":"B143","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1158\/0008-5472.CAN-11-1145","article-title":"Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy","volume":"71","author":"Liu","year":"2011","journal-title":"Cancer Res."},{"key":"B144","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of resistance to antibody\u2013drug conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"B145","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B146","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/ijms17040561","article-title":"Linkers having a crucial role in antibody-drug conjugates","volume":"17","author":"Lu","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B147","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/antib7010010","article-title":"Factors affecting the pharmacology of antibody-drug conjugates","volume":"7","author":"Lucas","year":"2018","journal-title":"Antibodies (Basel)"},{"key":"B148","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1039\/D2CB00094F","article-title":"Protein scaffolds: antibody alternatives for cancer diagnosis and therapy","volume":"3","author":"Luo","year":"2022","journal-title":"RSC Chem. Biol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"e35368","DOI":"10.7554\/eLife.35368","article-title":"Epigenetic drift of H3K27me3 in aging links glycolysis to healthy longevity in Drosophila","volume":"7","author":"Ma","year":"2018","journal-title":"eLife"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.3389\/fimmu.2018.02203","article-title":"Complement as a biological tool to control tumor growth","volume":"9","author":"Macor","year":"2018","journal-title":"Front. Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1158\/0008-5472.CAN-05-3434","article-title":"Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma","volume":"66","author":"Macor","year":"2006","journal-title":"Cancer Res."},{"key":"B152","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.imlet.2007.04.014","article-title":"Complement as effector system in cancer immunotherapy","volume":"111","author":"Macor","year":"2007","journal-title":"Immunol. Lett."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1158\/1535-7163.MCT-06-0686","article-title":"Tumor-stroma interactions in pancreatic ductal adenocarcinoma","volume":"6","author":"Mahadevan","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"B154","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B155","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/antib10020020","article-title":"Clinical pharmacology of antibody-drug conjugates","volume":"10","author":"Mahmood","year":"2021","journal-title":"Antibodies (Basel)"},{"key":"B156","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.4161\/cbt.199","article-title":"Classical chemotherapy: mechanisms, toxicities and the therapeutic window","volume":"2","author":"Malhotra","year":"2003","journal-title":"Cancer Biol. Ther."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann. Oncol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12935-022-02679-8","article-title":"Potential of antibody\u2013drug conjugates (ADCs) for cancer therapy","volume":"22","author":"Marei","year":"2022","journal-title":"Cancer Cell Int."},{"key":"B159","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest. New Drugs"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3109\/10428194.2012.656102","article-title":"Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin","volume":"53","author":"Matsumoto","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"B161","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3390\/biomedicines9080872","article-title":"Advances and limitations of antibody drug conjugates for cancer","volume":"9","author":"Mckertish","year":"2021","journal-title":"Biomedicines"},{"key":"B162","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1177\/0192623318803059","article-title":"A brief introduction to antibody-drug conjugates for toxicologic pathologists","volume":"46","author":"Mecklenburg","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/IJWH.S178349","article-title":"Triple-negative breast cancer: current perspective on the evolving therapeutic landscape","volume":"11","author":"Mehanna","year":"2019","journal-title":"Int. J. Womens Health"},{"key":"B164","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B165","doi-asserted-by":"publisher","first-page":"PD3","DOI":"10.1158\/1538-7445.SABCS20-PD3-06","article-title":"Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer","volume":"81","author":"Modi","year":"2021","journal-title":"Cancer Res."},{"key":"B166","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"100501","DOI":"10.1016\/j.esmoop.2022.100501","article-title":"Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis","volume":"7","author":"Nader-Marta","year":"2022","journal-title":"ESMO Open"},{"key":"B168","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/dddt.s4378","article-title":"Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC","volume":"3","author":"Natsume","year":"2009","journal-title":"Drug Des. Devel Ther."},{"key":"B169","first-page":"3","article-title":"Antibody-drug conjugates: Possibilities and challenges","volume":"11","author":"Nejadmoghaddam","year":"2019","journal-title":"Avicenna J. Med. Biotechnol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B171","doi-asserted-by":"publisher","first-page":"102395","DOI":"10.1016\/j.ctrv.2022.102395","article-title":"Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives","volume":"106","author":"Nicol\u00f2","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"B172","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-1-62703-541-5_5","article-title":"Linker technologies for antibody-drug conjugates","volume":"1045","author":"Nolting","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: Mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"key":"B174","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/978-1-62703-541-5_17","article-title":"Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography","volume":"1045","author":"Ouyang","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1021\/acsinfecdis.2c00492","article-title":"Development of host-cleavable antibody-bactericide conjugates against extracellular pathogens","volume":"9","author":"O\u2019Leary","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"B176","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.anl.2022.06.004","article-title":"Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma","volume":"50","author":"Omura","year":"2023","journal-title":"Auris Nasus Larynx"},{"key":"B177","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/molecules24152754","article-title":"Pharmacokinetic and metabolism studies of monomethyl auristatin F via liquid chromatography-quadrupole-time-of-flight mass spectrometry","volume":"24","author":"Park","year":"2019","journal-title":"Molecules"},{"key":"B178","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1158\/0008-5472.CAN-13-2990","article-title":"Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids","volume":"74","author":"Perrino","year":"2014","journal-title":"Cancer Res."},{"key":"B179","doi-asserted-by":"publisher","first-page":"e00225","DOI":"10.1042\/BSR20150089","article-title":"Antibody\u2013drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci. Rep."},{"key":"B180","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/antib10040042","article-title":"Introduction to antibody-drug conjugates","volume":"10","author":"Pettinato","year":"2021","journal-title":"Antibodies"},{"key":"B181","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","article-title":"Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models","volume":"18","author":"Ponte","year":"2016","journal-title":"Neoplasia"},{"key":"B182","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/ijms21155510","article-title":"Antibody-drug conjugates: The new frontier of chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B183","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cai2.8","article-title":"Expert consensus on the clinical application of antibody-drug conjugates in the treatment of malignant tumors (2021 edition)","volume":"1","year":"2022","journal-title":"Cancer Innov."},{"key":"B184","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","article-title":"LRRC15 is a novel mesenchymal protein and stromal target for antibody\u2013drug conjugates","volume":"78","author":"Purcell","year":"2018","journal-title":"Cancer Res."},{"key":"B185","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"MAbs"},{"key":"B186","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","article-title":"Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer","volume":"66","author":"Rassy","year":"2022","journal-title":"Breast"},{"key":"B187","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of action of therapeutic antibodies for cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol. Immunol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ddtec.2018.10.005","article-title":"Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery","volume":"30","author":"Richards","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res."},{"key":"B190","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","article-title":"Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer","volume":"23","author":"Sabbaghi","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B191","doi-asserted-by":"publisher","first-page":"188499","DOI":"10.1016\/j.bbcan.2020.188499","article-title":"CCR7 as a therapeutic target in Cancer","volume":"1875","author":"Salem","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B192","doi-asserted-by":"publisher","first-page":"114408","DOI":"10.1016\/j.biopha.2023.114408","article-title":"A comprehensive review of key factors affecting the efficacy of antibody drug conjugate","volume":"161","author":"Samantasinghar","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B193","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","article-title":"Advances in antibody-drug conjugates: A new era of targeted cancer therapy","volume":"22","author":"Sau","year":"2017","journal-title":"Drug Discov. Today"},{"key":"B194","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/9781119477891.ch27","article-title":"Progress in the development of single-use solutions in antibody\u2013drug conjugate (ADC) manufacturing","volume-title":"Single-use technology in biopharmaceutical manufacture","author":"Schmidhalter","year":"2019"},{"key":"B195","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMp048021","article-title":"Paul Ehrlich\u2019s magic bullets","volume":"350","author":"Schwartz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B196","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: A review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B197","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"B198","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B199","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv."},{"key":"B200","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","article-title":"Controlled drug delivery vehicles for cancer treatment and their performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal Transduct. Target Ther."},{"key":"B201","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cbpa.2009.03.023","article-title":"Potent antibody drug conjugates for cancer therapy","volume":"13","author":"Senter","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","article-title":"Antibody-targeted drugs and drug resistance--challenges and solutions","volume":"18","author":"Shefet-Carasso","year":"2015","journal-title":"Drug Resist Updat"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"B205","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s10120-021-01196-3","article-title":"Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer","volume":"24","author":"Shitara","year":"2021","journal-title":"Gastric Cancer"},{"key":"B207","doi-asserted-by":"publisher","first-page":"59615","DOI":"10.3791\/59615","article-title":"Characterization of proteins by size-exclusion chromatography coupled to multi-angle light scattering (SEC-MALS)","volume":"2019","author":"Some","year":"2019","journal-title":"J. Vis. Exp."},{"key":"B208","doi-asserted-by":"publisher","first-page":"26583","DOI":"10.1074\/jbc.M113.480483","article-title":"Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines","volume":"288","author":"Spiess","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"B210","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/ncomms1608","article-title":"Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential","volume":"2","author":"Stapleton","year":"2011","journal-title":"Nat. Commun."},{"key":"B211","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nbt.3274","article-title":"Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading","volume":"33","author":"Strop","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: Recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"B213","doi-asserted-by":"publisher","first-page":"13613","DOI":"10.1039\/D1SC02973H","article-title":"Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody\u2013drug conjugates","volume":"12","author":"Sun Kang","year":"2021","journal-title":"Chem. Sci."},{"key":"B214","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B215","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1172\/JCI120481","article-title":"Tumor stroma\u2013targeted antibody-drug conjugate triggers localized anticancer drug release","volume":"128","author":"Szot","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B216","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"B217","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2217\/imt-2018-0081","article-title":"Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases","volume":"11","author":"Talotta","year":"2019","journal-title":"Immunotherapy"},{"key":"B218","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fphar.2019.00373","article-title":"The analysis of key factors related to ADCs structural design","volume":"10","author":"Tang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jtbi.2012.08.034","article-title":"A mechanistic compartmental model for total antibody uptake in tumors","volume":"314","author":"Thurber","year":"2012","journal-title":"J. Theor. Biol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B222","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B223","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2014-07-588376","article-title":"Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies","volume":"125","author":"Tipton","year":"2015","journal-title":"Blood"},{"key":"B224","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.3390\/molecules26195847","article-title":"An insight into FDA approved antibody-drug conjugates for cancer therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"key":"B225","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"B226","doi-asserted-by":"publisher","first-page":"e2301340","DOI":"10.1002\/advs.202301340","article-title":"Antibody-drug conjugates to treat bacterial biofilms via targeting and extracellular drug release","volume":"10","author":"Tvilum","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"key":"B227","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.leu.2403350","article-title":"High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients","volume":"18","author":"van der Velden","year":"2004","journal-title":"Leukemia"},{"key":"B228","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1158\/0008-5472.CAN-21-0952","article-title":"Improving tumor penetration of antibodies and antibody-drug conjugates: Taking away the barriers for trojan horses","volume":"81","author":"van Dongen","year":"2021","journal-title":"Cancer Res."},{"key":"B229","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/14737140.2022.2093191","article-title":"Polatuzumab vedotin in relapsed\/refractory aggressive B-cell lymphoma","volume":"22","author":"Varma","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B230","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s13346-013-0176-5","article-title":"Questioning the use of PEGylation for drug delivery","volume":"3","author":"Verhoef","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"B231","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"B232","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"B233","doi-asserted-by":"publisher","first-page":"102500","DOI":"10.1016\/j.ctrv.2022.102500","article-title":"The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer","volume":"113","author":"von Arx","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"B234","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B235","doi-asserted-by":"publisher","first-page":"21","DOI":"10.23736\/S0031-0808.20.04149-X","article-title":"Monoclonal antibodies in multiple myeloma","volume":"63","author":"Vozella","year":"2021","journal-title":"Panminerva Med."},{"key":"B236","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fonc.2012.00062","article-title":"Trastuzumab: updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Vu","year":"2012","journal-title":"Front. Oncol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/19420862.2017.1412025","article-title":"Challenges and new frontiers in analytical characterization of antibody-drug conjugates","volume":"10","author":"Wagh","year":"2018","journal-title":"MAbs"},{"key":"B238","doi-asserted-by":"publisher","first-page":"113166","DOI":"10.1016\/j.jpba.2020.113166","article-title":"Determination of size variants by CE-SDS for approved therapeutic antibodies: Key implications of subclasses and light chain specificities","volume":"184","author":"Wagner","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B239","doi-asserted-by":"publisher","first-page":"e0160890","DOI":"10.1371\/journal.pone.0160890","article-title":"Structural basis of microtubule destabilization by potent auristatin anti-mitotics","volume":"11","author":"Waight","year":"2016","journal-title":"PLoS One"},{"key":"B240","doi-asserted-by":"publisher","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"B241","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: Recent advances in payloads","volume":"2023","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"B242","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1158\/1078-0432.CCR-19-3980","article-title":"FDA approval summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer","volume":"26","author":"Wedam","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"B243","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","article-title":"Monoclonal antibodies for cancer immunotherapy","volume":"373","author":"Weiner","year":"2009","journal-title":"Lancet"},{"key":"B244","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014New opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"B245","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"B246","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1007\/s11095-015-1729-8","article-title":"Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates","volume":"32","author":"Xu","year":"2015","journal-title":"Pharm. Res."},{"key":"B247","doi-asserted-by":"publisher","first-page":"1039882","DOI":"10.3389\/fonc.2022.1039882","article-title":"Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis","volume":"12","author":"Yao","year":"2023","journal-title":"Front. Oncol."},{"key":"B248","doi-asserted-by":"publisher","first-page":"10735","DOI":"10.1038\/s41598-017-11255-4","article-title":"Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease","volume":"7","author":"Yasunaga","year":"2017","journal-title":"Sci. Rep."},{"key":"B249","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neuron.2016.09.036","article-title":"Microtubule organization determines axonal transport dynamics","volume":"92","author":"Yogev","year":"2016","journal-title":"Neuron"},{"key":"B250","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B251","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"B252","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"B253","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1021\/acs.biochem.8b00575","article-title":"Structural changes and aggregation mechanisms of two different dimers of an IgG2 monoclonal antibody","volume":"57","author":"Zhang","year":"2018","journal-title":"Biochemistry"},{"key":"B254","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","article-title":"Recent advances of antibody drug conjugates for clinical applications","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"B255","doi-asserted-by":"publisher","first-page":"648407","DOI":"10.3389\/fphar.2021.648407","article-title":"Clinically-relevant ABC transporter for anti-cancer drug resistance","volume":"12","author":"Zheng","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B256","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/cancers15102718","article-title":"Beyond CTLA-4 and PD-1 inhibition: Novel immune checkpoint molecules for melanoma treatment","volume":"15","author":"Ziogas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B257","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jchromb.2016.05.055","article-title":"A simple LC\/MRM-MS-based method to quantify free linker-payload in antibody-drug conjugate preparations","volume":"1032","author":"Zmolek","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1274088\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T03:30:02Z","timestamp":1695094202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1274088\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":257,"alternative-id":["10.3389\/fphar.2023.1274088"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1274088","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"article-number":"1274088"}}